| Acromegaly
Signifor LAR vs Somavert
Side-by-side clinical, coverage, and cost comparison for acromegaly.Deep comparison between: Signifor Lar vs Somavert with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSomavert has a higher rate of injection site reactions vs Signifor Lar based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Somavert but not Signifor Lar, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Signifor Lar
Somavert
At A Glance
IM injection
Every 4 weeks
Somatostatin analog
SC injection
Daily
GH receptor antagonist
Indications
- Acromegaly
- Pituitary-dependent Cushing's disease
- Acromegaly
Dosing
Acromegaly Initial dose 40 mg by IM injection once every 4 weeks; may increase to maximum 60 mg every 4 weeks based on response and tolerability. Child-Pugh B: initial dose 20 mg, maximum 40 mg once every 4 weeks. Avoid in Child-Pugh C.
Pituitary-dependent Cushing's disease Initial dose 10 mg by IM injection once every 4 weeks; may increase up to maximum 40 mg once every 28 days based on response and tolerability. Child-Pugh B: initial dose 10 mg, maximum 20 mg once every 4 weeks. Avoid in Child-Pugh C.
Acromegaly 40 mg SC loading dose under physician supervision, then 10 mg SC once daily starting the next day; titrate in 5 mg increments or decrements every 4-6 weeks to normalize IGF-1; maintenance range 10-30 mg SC once daily.
Contraindications
—
—
Adverse Reactions
Most common (>=5%) Hyperglycemia, diabetes mellitus, diarrhea, cholelithiasis, headache, nausea, abdominal pain, fatigue, alopecia, sinus bradycardia, nasopharyngitis, blood creatine phosphokinase increased
Serious Hyperglycemia, ketoacidosis, bradycardia, QT prolongation, liver test elevations, cholelithiasis and complications, pituitary hormone deficiency, steatorrhea and malabsorption of dietary fats
Postmarketing Cholelithiasis resulting in complications including cholecystitis and cholangitis, sometimes requiring cholecystectomy
Most common Infection, pain, nausea, diarrhea, abnormal liver function tests, flu syndrome, injection site reaction, dizziness
Serious Transaminase elevations >10x ULN, hepatotoxicity, lipohypertrophy, systemic hypersensitivity reactions
Postmarketing Anaphylactic reactions, laryngospasm, angioedema, rash, erythema, pruritus, urticaria
Pharmacology
Pasireotide is a somatostatin analog (cyclohexapeptide) that binds with high affinity to somatostatin receptor subtypes SSTR1, 2, 3, and 5, inhibiting GH secretion in acromegaly and ACTH secretion in Cushing's disease via SSTR2 and SSTR5 activation, leading to decreased cortisol secretion.
GH receptor antagonist; pegvisomant selectively binds to growth hormone (GH) receptors on cell surfaces, blocking endogenous GH binding and interfering with GH signal transduction, resulting in decreased serum concentrations of IGF-1, free IGF-1, ALS, and IGFBP-3.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Signifor Lar
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (9/12)
Somavert
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Signifor Lar
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Somavert
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (8/8) · Qty limit (4/8)
Humana
Signifor Lar
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Somavert
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Acromegaly: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$5/momo
Somavert Copay ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Signifor LarView full Signifor Lar profile
SomavertView full Somavert profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.